AMDL has terminated a previously announced LOI to acquire Guangzhou Lazon Pharmacy Co., Ltd. (GLP), a Guangzhou-based distributor based on material uncovered through the due diligence process.
AMDL, Inc. is a specialty pharmaceutical company. The Company is headquartered in Tustin, California with operations in Shenzhen, Jiangxi, and Jilin, China. Along with its subsidiary Jade Pharmaceutical Inc. (JPI), AMDL is devoted to the research, development, manufacturing, and marketing of diagnostic, pharmaceutical, nutritional supplement, and cosmetic products currently in China. The company employs approximately 320 people in the U.S. and China. More information about AMDL and its products can be obtained at http://www.amdl.com.
About Jade Pharmaceutical:
JPI has access to the fastest growing pharmaceutical and consumer market in the world: China. AMDL, through its subsidiary Jade, currently manufactures large volume injection fluids, tablets and other related products, holding licenses for 133 products. It also manufactures 107 generic, over the counter and supplemental pharmaceutical products under certified Chinese Good Manufacturing Practice (CGMP) standards.
Statements in this press release may constitute forward-looking
statements and are subject to numerous risks and uncertainties, including
the failure to complete successfully the development of new or enhanced
products, the Company's future capital needs, the lack of market demand for
any new or enhanced products the Company may develop, any actions by the
Company's partners that may be adverse
|SOURCE AMDL, Inc.|
Copyright©2008 PR Newswire.
All rights reserved